Hospira

Activities: Drug Delivery Pharmaceutical

Trending Articles

  1. From data to decisions: applying criticality and failure probability in process risk mitigation This article presents an exploration of how structured, data-based methods enhance quality control, optimise specifications and improve process robustness throughout the...
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Stop reviewing good data: review‑by‑exception for chromatography QC Labs spend hours confirming routine chromatograms while real risks hide in plain sight; regulators support a better path if data are captured and surfaced correctly, notes...
  3. SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the...
  4. Manufacturing Chemist Stand Side with GEA and Hovione We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  5. Vileda Professional CE launches revolutionary single-use microfibre mopping system Vileda Professional CE launches revolutionary single-use microfibre mopping system for cleanrooms and controlled environments

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Regulatory

FDA cautions Pfizer subsidiary in India in quality control warning letter

The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery

Mylan and Hospira voluntarily recall injectables

Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory

Brussels explains why it approved Pfizer/Hospira deal

Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory

Hospira calls for biosimilars to have same name as biologicals

Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development

Hospira and Pfenex link up to develop Lucentis biosimilar

Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery

Pfizer to acquire Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing

Opinion: Still not getting it right

The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now